NEW YORK, Dec. 13 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX), announced today that it has received notification from several
companies that they have filed Abbreviated New Drug Applications (ANDA)
with Paragraph IV Certifications to obtain approval to market generic
equivalents of Namenda, an NMDA receptor antagonist indicated for the
treatment of moderate to severe dementia of the Alzheimer's type. The
Company intends to pursue all appropriate legal action to defend its
intellectual property related to Namenda. Namenda is covered by an issued
U.S. patent which is set to expire in April 2010. Forest has applied for
patent term restoration which, if granted, would extend Namenda's patent
protection until September 2013.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
Except for the historical information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform act of 1995. These statements involve a number
of risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to time in
each of Forest Laboratories' Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q, and any subsequent SEC filings.
SOURCE Forest Laboratories, Inc.
 back to top
Related links:
http://www.frx.com/
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Charles E. Triano, Vice President - Investor
Relations of Forest Laboratories, Inc., +1-212-224-6714,
charles.triano@frx.com
|
